Background/Objectives: Cancer- or chemotherapy-related cognitive deficit is a common side effect occurring in patients with Hodgkin lymphoma. No previous study compared the influence of different types of treatment on the onset and development of chemotherapy cognitive impairment in longitudinal design. The aim of this study was to assess whether a more intensive form of chemotherapy causes greater cognitive impairment. Methods: Forty-four patients at three different stages of the disease and with three different treatments (ABVD + 30 Gy, BEACOPPesc, or ABVD + 30 Gy plus BEACOPPesc) completed the neuropsychological battery and psychological measures of affective distress and quality of life. We compared their cognitive performance before, immediately after, and 6 months after the treatment. Results: Whether or not we divided the total number of people with Hodgkin lymphoma into two groups (mild and moderate disease versus severe disease) or three groups (mild, moderate, and advanced disease), we found no statistically significant difference between the groups in cognitive performance or other psychological factors or experienced quality of life. Conclusions: Our results did not show that disease stage or treatment protocol had an effect on the depth of cognitive impairment in cancer or chemotherapy. We hypothesize that, in terms of brain health, intensive forms of chemotherapy (6 × BEA-COPPesc) do not pose a greater risk than milder forms (4 × ABVD + 30 Gy IF RT and 2 × BEACOPPesc + 4 × ABVD + 30 Gy IF RT) of cancer treatment for Hodgkin lymphoma. However, a limitation of our study is the small number of participants in the study, so it would be advisable to repeat the study on a larger sample of patients. Confirmation of our results could be beneficial in that neither patients nor physicians need to worry that intensive chemotherapy will worsen cognitive deficits.
背景/目的：癌症或化疗相关认知功能障碍是霍奇金淋巴瘤患者常见的副作用。既往尚无研究在纵向设计中比较不同类型治疗对化疗认知障碍发生发展的影响。本研究旨在评估更强化化疗方案是否会导致更严重的认知损伤。方法：44名处于不同疾病阶段并接受三种不同治疗方案（ABVD+30Gy、BEACOPPesc或ABVD+30Gy联合BEACOPPesc）的患者完成了神经心理学测试及情感困扰与生活质量的心理学评估。我们比较了治疗前、治疗后即刻及治疗后6个月患者的认知表现。结果：无论将霍奇金淋巴瘤患者总体分为两组（轻中度疾病组与重度疾病组）还是三组（轻度、中度及晚期疾病组），各组间在认知表现、其他心理因素或生活质量体验方面均未发现统计学显著差异。结论：我们的研究结果未显示疾病分期或治疗方案对癌症或化疗相关认知障碍的严重程度产生影响。我们推测，就大脑健康而言，强化化疗方案（6×BEA-COPPesc）并不比温和方案（4×ABVD+30Gy IF RT及2×BEACOPPesc+4×ABVD+30Gy IF RT）对霍奇金淋巴瘤患者构成更大风险。但本研究存在样本量较小的局限，建议在更大患者样本中重复验证。若结果得到证实，将具有重要临床意义：患者和医生都无需担忧强化化疗会加重认知缺陷。
肿瘤(癌症)患者之家